TRAVERE THERAPEUTICS, INC. (TVTX) Free cash flow 2016–2023
TRAVERE THERAPEUTICS, INC. (TVTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$280.7MFY2023 · since FY2016: -$4.9M → -$280.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$280.7M | -50.5% |
| FY2022 | -$186.5M | -837.4% |
| FY2021 | -$19.9M | +59.8% |
| FY2020 | -$49.5M | +15.2% |
| FY2019 | -$58.4M | -127.4% |
| FY2018 | -$25.7M | -494.2% |
| FY2017 | $6.5M | +233.8% |
| FY2016 | -$4.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Net marginTVTX Gross profitTVTX Gross marginTVTX Operating incomeTVTX Operating marginTVTX Operating cash flowTVTX Capital expendituresTVTX Return on equityTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Total liabilitiesTVTX Shareholders’ equityTVTX overview →